Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Edwards Lifesciences Corporation Revenue & Financial Statements
Edwards Lifesciences Corporation reported revenue of $(20.4M) for the fiscal year ended December 31, 2025, up 3.0% year over year, with net income of $1.1B and diluted EPS of $1.83.
- Company
- Edwards Lifesciences Corporation EW · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 5.2B | 5.4B | 6.0B | (19.8M) | (20.4M) |
| Cost of revenue | 1.2B | 1.1B | 1.4B | 1.1B | 1.3B |
| Gross profit | 4.0B | 4.3B | 4.6B | 4.3B | 4.7B |
| Operating income | 1.7B | 1.7B | 1.5B | 1.4B | 1.3B |
| Pretax income | 1.1B | 1.1B | 1.3B | 1.3B | 1.4B |
| Net income | 1.5B | 1.4B | 1.4B | 4.2B | 1.1B |
| Diluted EPS | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
| EBITDA | 1.8B | 1.9B | 1.7B | 1.5B | 1.4B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.5M | 15.5M | 24.3M | (76.1M) | 36.5M | 37.4M | 38.6M | (132.9M) |
| Cost of revenue | 385.6M | 285.3M | 262.9M | 292.2M | 301.6M | 344.4M | 345.2M | 343.0M |
| Gross profit | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B | 1.2B |
| Operating income | 387.5M | 369.1M | 350.6M | 312.6M | 394.8M | 411.2M | 307.1M | 151.1M |
| Pretax income | 409.4M | 386.6M | 402.8M | 390.1M | 433.9M | 400.2M | 348.4M | 90.4M |
| Net income | 361.4M | 379.4M | 3.0B | 393.6M | 348.0M | 323.6M | 304.8M | 91.2M |
| Diluted EPS | 0.58 | 0.61 | 5.13 | 0.68 | 0.61 | 0.56 | 0.50 | 0.16 |
| EBITDA | 426.0M | — | 385.1M | 355.2M | 431.4M | — | 346.3M | 193.8M |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 8.5B | 8.3B | 9.4B | 13.1B | 13.7B |
| Current assets | 3.2B | 3.1B | 4.0B | 6.3B | 6.7B |
| Cash & equivalents | 862.8M | 769.0M | 1.1B | 3.0B | 2.9B |
| Total liabilities | 2.7B | 2.5B | 2.6B | 3.0B | 3.4B |
| Current liabilities | 1.0B | 1.0B | 1.2B | 1.5B | 1.8B |
| Long-term debt | 595.7M | 596.3M | 597.0M | 597.7M | 598.3M |
| Total debt | 595.7M | 596.3M | 597.0M | 597.7M | 598.3M |
| Stockholders’ equity | 5.8B | 5.8B | 6.7B | 10.0B | 10.3B |
| Net debt | (267.1M) | (172.7M) | (547.0M) | (2.4B) | (2.3B) |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 1.7B | 1.2B | 895.8M | 542.3M | 1.6B |
| Investing cash flow | (1.7B) | 252.3M | 173.8M | 2.3B | (712.9M) |
| Financing cash flow | (356.3M) | (1.6B) | (711.0M) | (983.0M) | (956.8M) |
| Capital expenditure | 325.8M | 244.6M | 253.0M | 252.4M | 260.2M |
| Free cash flow | 1.4B | 973.6M | 642.8M | 289.9M | 1.3B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 109.3M | 126.8M | 139.4M | 162.3M | 158.1M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every EW filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.